Skip to main content

Mercedes Arrue Gonzalo

I graduated in biology with a specialty in neurobiology in Madrid. After completing a master's degree in pharmacological research, I completed my PhD investigating the influence of diesel exhaust particles on ischemic stroke in the group of neurovascular diseases. Where I currently continue to develop my work.

Institutions of which they are part

Postdoctoral researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Mercedes Arrue Gonzalo

Institutions of which they are part

Postdoctoral researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

I graduated in biology with a specialty in neurobiology in Madrid. After completing a master's degree in pharmacological research, I completed my PhD investigating the influence of diesel exhaust particles on ischemic stroke in the group of neurovascular diseases. Where I currently continue to develop my work.

PhD in Neuroscience (2018-2022)
Master in Pharmacological research (2017-2018)
Degree in Biology (2007-2013)

Projects

Incorporació Dr. Joan Montaner a la RETICS en Malalties vasculars cerebrals (ICTUS)

IP: -
Collaborators: Anna Rosell Novel, Mercedes Arrúe Gonzalo, Marcel Lamana Vallverdu, Anna Penalba Morenilla, Maria Mar Hernandez Guillamon, Maria Pilar Delgado Martínez, Guillem Colell Dinares, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel, Anna Rosell Novel
Funding agency: Instituto de Salud Carlos III
Funding: 240669
Reference: RD16/0019/0021
Duration: 01/01/2017 - 31/12/2021

Related news

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

Related professionals

Alejandro Tomasello Weitz

Alejandro Tomasello Weitz

Stroke research
Read more
Marcelo A. Casaccia

Marcelo A. Casaccia

Reconstructive Surgery of the Locomotor System
Read more
Marco Inzitari

Marco Inzitari

Head of group
Research on Aging, Frailty and Transitions in Barcelona
Read more
Sofia  Contreras  Medina

Sofia Contreras Medina

Predoctoral researcher
Shock, Organ Dysfunction and Resuscitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.